Pharmaceuticals segment

As discussed earlier, GlaxoSmithKline’s (GSK) pharmaceuticals segment revenues saw growth of 17% to ~4.2 billion pounds in 1Q17 as compared to 1Q16. This includes an operational growth of 4% and a positive impact from foreign exchange. The growth was driven by increased sales of HIV products Triumeq and Tivicay, and new pharmaceutical products including Relvar, Breo, Ellipta, and Nucala, partially offset by the impact of divestments.

How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 1Q17?

Overall, the pharmaceutical segment’s contribution to total revenues was 56.7% in 1Q17. The pharmaceuticals segment consists of various franchises including HIV products, respiratory products, immuno-inflammation products, and established products.

HIV products

The company’s HIV products are marketed under ViiV healthcare, a company with GSK as a major shareholder. Pfizer (PFE) and Shionogi are other shareholders. HIV products reported growth of 19% at constant exchange rates to 985 million pounds in 1Q17 as compared to 1Q16. HIV products contribute over 23% of the total pharmaceuticals segment sales.

Global pharmaceuticals

The global pharmaceuticals business deals with respiratory, immuno-inflammation, and established products. The company’s global pharmaceuticals segment reported revenues of 3.20 billion pounds in 1Q17. This includes a 5% growth in respiratory sales at constant exchange rates to 1.68 billion pounds, a 23% growth in immuno-inflammation sales at constant exchange rates to 92 million pounds, and a 6% decline in established pharmaceuticals sales at constant exchange rates to 1.43 billion pounds during 1Q17.

To divest the risk, investors can consider ETFs like the Vanguard FTSE All-World Ex-US ETF (VEU), which holds 0.6% of its total assets in GlaxoSmithKline. VEU also holds 1.2% of its total assets in Novartis (NVS), 0.6% in Sanofi (SNY), and 0.5% in AstraZeneca (AZN).

Latest articles

German chip maker Infineon Technologies has reportedly raised 1.55 billion euros (~$1.74 billion) in capital by selling its shares to fund its acquisition of Cypress Semiconductor (CY). Infineon has sold ~113 million new shares at 13.70 euros each.

As of June 18, Dunkin’ Brands (DNKN) was trading at $80.07, an 8.9% rise since reporting its first-quarter earnings on May 2. Also, DNKN was trading at a premium of 29.8% from its 52-week low of $61.69 and a discount of 1.6% from its 52-week high of $81.40.

19 Jun

Are Lower Oil Prices Weighing on ExxonMobil Stock?

WRITTEN BY Maitali Ramkumar

ExxonMobil (XOM) stock has fallen 7.1% in the second quarter so far. Let's review ExxonMobil's stock performance in comparison to oil price changes and equity market movements in the quarter.

19 Jun

As Facebook Unveils Libra, MSFT and CRM Join a Blockchain Group

WRITTEN BY Mayur Sontakke, CFA, FRM

On June 18, Facebook (FB) launched Libra, its own cryptocurrency. On the same day, CoinDesk published another piece of blockchain news that didn’t receive as much fanfare as Facebook’s Libra news. Was the timing a coincidence? We think not.

Uber Technologies (UBER) has picked Melbourne as another test site for its flying taxi service known as UberAir. The Australian city is the first international test site Uber has chosen for its flying taxi service. The addition of Melbourne brings the number of test locations Uber has picked for its UberAir service to three.

Lyft (LYFT) and Uber Technologies (UBER) are pushing back against California legislation that would require them to recognize their drivers as employees rather than independent contractors. The legislation would require companies like Lyft to give their drivers the compensation and benefits spelled out under California’s employment regulations.